BiotechTube

AAV RPE65

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Leber Congenital Amaurosis

Conditions

Leber Congenital Amaurosis

Trial Timeline

Apr 1, 2016 → Dec 1, 2018

NCT ID
NCT02781480

About AAV RPE65

AAV RPE65 is a phase 1/2 stage product being developed by MeiraGTx for Leber Congenital Amaurosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02781480. Target conditions include Leber Congenital Amaurosis.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT02781480Phase 1/2Completed

Competing Products

12 competing products in Leber Congenital Amaurosis

See all competitors
ProductCompanyStageHype Score
EDIT-101Editas MedicinePhase 1/2
33
AAV OPTIRPE65MeiraGTxPre-clinical
15
Idebenone + PlaceboSanthera PharmaceuticalsPhase 2
44
IdebenoneSanthera PharmaceuticalsApproved
77
Idebenone 150 MG Oral TabletSanthera PharmaceuticalsPre-clinical
15
IdebenoneSanthera PharmaceuticalsPre-clinical
15
sepofarsenProQRPhase 2/3
57
sepofarsenProQRPhase 2/3
57
Idebenone + PlaceboSanthera PharmaceuticalsPhase 3
69
GS010GenSight BiologicsPhase 3
69
GS010GenSight BiologicsPhase 3
69
PlaceboGenSight BiologicsPhase 3
69

Other Products from MeiraGTx

AAV - CNGB3Phase 1/2
33
adeno-associated virus vector AAV- CNGA3Phase 1/2
33
AAV2hAQP1Phase 1
25
AAV2hAQP1: 1 x 10^11 vg/gland (single gland) + AAV2hAQP1: 3 x 10^10 vg/gland (both glands) + AAV2hAQP1: 3 x 10^11 vg/gland (single gland) + AAV2hAQP1: 1 x 10^11 vg/gland (both glands) + AAV2hAQP1: 1 x 10^12 vg/gland (single gland) + AAV2hAQP1: 3 x 10^11 vg/gland (both glands) + AAV2hAQP1: 3 x 10^12 vg/gland (single gland) + AAV2hAQP1: 1 x 10^12 vg/gland (both glands)Phase 1
25
AAV OPTIRPE65Pre-clinical
15